Interestingly, FAS inhibition was previously demonstrated to improve non-alcoholic fatty liver diseases and non-alcoholic steatohepatitis by reducing inflammatory markers IL-1β and reducing transaminitis (elevated serum ALT and AST)60,65. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.